Clinical Evaluation of Ultrasound-Enhanced Radiotracer Uptake for Radioligand Therapy in Metastatic Prostate Cancer | Synapse
April 13, 2026
Clinical Evaluation of Ultrasound-Enhanced Radiotracer Uptake for Radioligand Therapy in Metastatic Prostate Cancer
Key Points
The aim is to evaluate the safety and effectiveness of ultrasound-enhanced radiotracer therapy in metastatic prostate cancer.
Clinical evaluation of ultrasound-enhanced radiotracer therapy (RLT)
Assessment of intratumoral radiotracer uptake
Measurement of biochemical control and progression-free survival (PFS)
Ultrasound-enhanced RLT is shown to be safe
Increased intratumoral radiotracer uptake is observed
Improved biochemical control and progression-free survival (PFS) reported
Abstract
US-enhanced RLT appears safe and can increase intratumoral radiotracer uptake, translating into improved biochemical control and PFS in metastatic prostate cancer.